Figure 1 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, mild-to-moderate disease. Figure 2 Statistical model of historical 1-year declines on ADAS-Cog, placebo vs simufilam treatment, in early disease and mild disease. ADAS-Cog mean scores changed...

AUSTIN, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following a brief journey with cancer, only recently discovered. We mourn profoundly the passing of a cherished...

PHILADELPHIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Investor protection law firm Kaskela Law LLC announces that it is investigating Cassava Sciences, Inc. (Cassava or the Company) (NASDAQ: SAVA) on behalf of the Companys long-term investors. On November 17, 2021, The Wall Street Journal reported that ...

Outside Biostatisticians with Specific Expertise in Alzheimers Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately Year-End 2022, Pending Completion of Study Report by Outside Biostatisticians. AUSTIN, Texas, Dec. 06, 2022...

AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the Company or Cassava Sciences), a clinical-stage biotechnology company focused on Alzheimers disease, today announced the closing of its previously announced registered direct offering of 1,666,667 shares of ...